Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio

AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.

Companies Gene Therapy

GSK Poaches New Vaccines R&D Chief From Pfizer

Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.

Companies Coronavirus COVID-19

GSK Looks To Long-Acting Therapy To Restore Lead In HIV

GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.

Companies Research & Development

COVID-19 Vaccine Makers Pledge Rapid Response To Omicron Threat

While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.

Coronavirus COVID-19 Companies

Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions

Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.

Companies Commercial

Gilead Trial Pause Adds To Merck & Co’s HIV Concerns

The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.

Infectious Diseases Companies
See All
UsernamePublicRestriction

Register